Development and Evaluation of a Pseudovirus-Luciferase Assay for Rapid and Quantitative Detection of Neutralizing Antibodies against Enterovirus 71

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wu, Xing ^a,b   Mao, Qunying ^b   Yao, Xin ^b   Chen, Pan ^c   Chen, Xiangmei ^a   Shao, Jie ^b   Gao, Fan ^b   Yu, Xiang ^d   Zhu, Fengcai ^e   Li, Rongcheng ^f   Li, Wenhui ^c   Liang, Zhenglun ^b   Wang, Junzhi ^b   Lu, Fengmin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING HOSPITAL   (China)

^c NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES   (China)

^d Hualan Biological Engineering Inc   (China)

^e JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; FIREFLY LUCIFERASE; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS REACTION; CYTOPATHOGENIC EFFECT; ENTEROVIRUS 71; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; NONHUMAN; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PSEUDOVIRUS LUCIFERASE ASSAY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL (TOPIC); ENTEROVIRUS; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; INFANT; PHYSIOLOGY; PRESCHOOL CHILD; REPRODUCIBILITY; SERODIAGNOSIS; TUMOR CELL LINE; VACCINATION; VIROLOGY; VIRUS ENTRY;

CAPRA HIRCUS; HEPATITIS A VIRUS; HUMAN ENTEROVIRUS 71;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE, TUMOR; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ENTEROVIRUS A, HUMAN; FEMALE; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFANT; LUCIFERASES, FIREFLY; MALE; NEUTRALIZATION TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VACCINATION; VIRAL VACCINES; VIRUS INTERNALIZATION;

EID: 84878769516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064116     Document Type: Article

References (32)

1. Hsu CH, Lu CY, Shao PL, Lee PI, Kao CL, et al. (2008) Epidemiologic and clinical features of non-polio enteroviral infections in northern Taiwan in 2008. J Microbiol Immunol Infect 44: 265-273.
2. Qiu J, (2008) Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 7: 868-869.
3. Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, et al. (1999) Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18: 1092-1096.
4. Schmidt NJ, Lennette EH, Ho HH, (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304-309.
5. Chang LY, (2008) Enterovirus 71 in Taiwan. Pediatr Neonatol 49: 103-112.
6. Chinese Center for Disease Control and Prevention website. National NotifiableInfectious Diseases Situation Update. Available: http://www.chinacdc.cn/tjsj/fdcrbbg/. Accessed 2013 April 17.
7. U.S. National Institutes of Health website. Available: http://clinicaltrials.gov/ct2/results?term=ev71. Accessed 2013 April 17.
8. AbuBakar S, Chan YF, Lam SK, (2000) Outbreaks of enterovirus 71 infection. N Engl J Med 342: 355-356.
9. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
10. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, et al. (2002) Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 109: e88.
11. Kung SH, Wang SF, Huang CW, Hsu CC, Liu HF, et al. (2007) Genetic and antigenic analyses of enterovirus 71 isolates in Taiwan during 1998-2005. Clin Microbiol Infect 13: 782-787.
12. Huang ML, Chiang PS, Luo ST, Liou GY, Lee MS, (2010) Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71. J Virol Methods 165: 42-45.
13. Montefiori DC (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
14. Wu X, Zhang C, Feng S, Liu C, Li Y, et al. (2009) Detection of HPV types and neutralizing antibodies in Gansu province, China. J Med Virol 81: 693-702.
15. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, et al. (2003) Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41: 5046-5052.
16. Earl PL, Americo JL, Moss B, (2003) Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 77: 10684-10688.
17. Mao QY, Liao XY, Yu X, Li N, Zhu FC, et al. (2010) Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin Med J (Engl) 123: 1679-1684.
18. Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, et al. (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.
19. Chen P, Song Z, Qi Y, Feng X, Xu N, et al. (2012) Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287: 6406-6420.
20. Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, et al. (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21: 1249-1273.
21. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-1862.
22. Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, et al. (2007) Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 81: 10310-10315.
23. Liu CC, Lian WC, Butler M, Wu SC, (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19-24.
24. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61-68.
25. Mao Q, Li N, Yu X, Yao X, Li F, et al. (2012) Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 157: 37-41.
26. Cambron P, Jacquet JM, Hoet B, Lievens M, (2009) Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine. Clin Vaccine Immunol 16: 1236-1246.
27. Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA, (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969-9975.
28. Oberste MS, Penaranda S, Maher K, Pallansch MA, (2004) Complete genome sequences of all members of the species Human enterovirus A. J Gen Virol. 85: 1597-1607.
29. Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, et al. (2009) An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 44: 262-267.
30. Yao X, Mao QY, Huang WJ, He P, Zhou C, et al. (2009) [Genetic characterization of enterovirus 71 complete genome isolated in Beijing, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi 30: 729-732.
31. Chen Y, Li C, He D, Cheng T, Ge S, et al. (2013) Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine 31: 425-430.
32. Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, et al. (2009) Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27: 3153-3158.